{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:29:36Z","timestamp":1791390576914,"version":"4.3.3"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation. Acyl coenzyme A (Acyl-CoA) synthetase long-chain family member 4 (ACSL4) promotes ferroptosis by enriching cellular membranes with polyunsaturated fatty acids, yet its prognostic relevance in melanoma remains unclear. We conducted a retrospective analysis of 63 patients with melanoma to evaluate associations between ACSL4 expression and overall survival (OS), metastasis-free survival (MFS), and disease-free survival (DFS). Correlation analyses and Cox proportional hazards (CoxPH) models were used to identify prognostic factors, and immune cell infiltration was assessed in tumor samples. Higher ACSL4 expression was consistently associated with improved OS, MFS, and DFS in cutaneous melanoma. ACSL4 levels also correlated with greater immune cell infiltration within the tumor microenvironment. Notably, metastatic melanoma cases exhibited higher ACSL4 expression than non-metastatic cases; however, within cutaneous melanoma, elevated ACSL4 remained linked to more favorable survival outcomes. Together, these findings position ACSL4 as a promising prognostic biomarker in melanoma and suggest a potential connection between ferroptosis biology and antitumor immunity. While the study is retrospective and correlative, it provides a strong rationale for prospective validation and mechanistic studies to test whether modulating ACSL4-driven ferroptosis can improve clinical outcomes.<\/jats:p>","DOI":"10.3389\/fmed.2025.1553961","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:10:09Z","timestamp":1773688209000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Acyl-CoA synthetase long-chain family member 4\u2014A novel prognostic marker in cutaneous melanoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Soumya","family":"Paria","sequence":"first","affiliation":[{"name":"School of Mathematics and Statistics, Faculty of Science, Technology, Engineering and Mathematics, The Open University","place":["Milton Keynes, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lapides","sequence":"additional","affiliation":[{"name":"The Robert Larner, M.D. College of Medicine at the University of Vermont","place":["Burlington, VT, United States"]},{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School","place":["Charlestown, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Saravi","sequence":"additional","affiliation":[{"name":"Department of Oral, Maxillofacial and Facial Plastic Surgery, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich-Heine-University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Connecticut","place":["Farmington, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina M.","family":"Torrez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"K\u00f6lblinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Paracelsus Medica University","place":["Salzburg, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang-Evers","sequence":"additional","affiliation":[{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School","place":["Charlestown, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Manstein","sequence":"additional","affiliation":[{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School","place":["Charlestown, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Navarini","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lazar","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Medical Center, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos V.","family":"Kem\u00e9ny","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University","place":["Budapest, Hungary"]},{"name":"HCEMM-SU Translational Dermatology Research Group, Semmelweis University","place":["Budapest, Hungary"]},{"name":"Department of Physiology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Sarek","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaustubh","family":"Adhikari","sequence":"additional","affiliation":[{"name":"School of Mathematics and Statistics, Faculty of Science, Technology, Engineering and Mathematics, The Open University","place":["Milton Keynes, United Kingdom"]},{"name":"Department of Genetics, Evolution and Environment, and UCL Genetics Institute, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n B.","family":"N\u00e9meth","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Szent-Gy\u00f6rgyi Albert Medical School, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Roider","sequence":"additional","affiliation":[{"name":"Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School","place":["Charlestown, MA, United States"]},{"name":"Department of Dermatology, University Hospital of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","article-title":"Necroptosis, pyroptosis and apoptosis: an intricate game of cell death","volume":"18","author":"Bertheloot","year":"2021","journal-title":"Cell Mol Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3892\/ijo.21.1.165","article-title":"Cell death: apoptosis versus necrosis [review]","volume":"21","author":"Kanduc","year":"2002","journal-title":"Int J Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","article-title":"Ferroptosis: process and function","volume":"23","author":"Xie","year":"2016","journal-title":"Cell Death Differ."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.bbrc.2016.08.124","article-title":"Identification of ACSL4 as a biomarker and contributor of ferroptosis","volume":"478","author":"Yuan","year":"2016","journal-title":"Biochem Biophys Res Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"949863","DOI":"10.3389\/fphar.2022.949863","article-title":"ACSL4 as a potential target and biomarker for anticancer: from molecular mechanisms to clinical therapeutics","volume":"13","author":"Hou","year":"2022","journal-title":"Front Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","article-title":"ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat Chem Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13062-021-00294-7","article-title":"High-fat diet impairs ferroptosis and promotes cancer invasiveness via downregulating tumor suppressor ACSL4 in lung adenocarcinoma","volume":"16","author":"Zhang","year":"2021","journal-title":"Biol Direct"},{"key":"B9","doi-asserted-by":"publisher","first-page":"103560","DOI":"10.1016\/j.ebiom.2021.103560","article-title":"Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy","volume":"71","author":"Sha","year":"2021","journal-title":"eBioMedicine."},{"key":"B10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bbrc.2021.01.028","article-title":"Oleanolic acid inhibits cervical cancer Hela cell proliferation through modulation of the ACSL4 ferroptosis signaling pathway","volume":"545","author":"Xiaofei","year":"2021","journal-title":"Biochem Biophys Res Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"816432","DOI":"10.3389\/fphar.2022.816432","article-title":"Propofol augments paclitaxel-induced cervical cancer cell ferroptosis in vitro","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3892\/ol.2018.8843","article-title":"Fatty acid activation in carcinogenesis and cancer development: essential roles of long-chain acyl-CoA synthetases [Review]","volume":"16","author":"Tang","year":"2018","journal-title":"Oncol Lett"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.3390\/cancers15245868","article-title":"Possible explanations for rising melanoma rates despite increased sunscreen use over the past several decades","volume":"15","author":"Lapides","year":"2023","journal-title":"Cancers."},{"key":"B14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/medsci9040063","article-title":"Epidemiology of Melanoma","volume":"9","author":"Saginala","year":"2021","journal-title":"Med Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"key":"B17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","article-title":"Adaptive linear step-up procedures that control the false discovery rate","volume":"93","author":"Benjamini","year":"2006","journal-title":"Biometrika."},{"key":"B19","unstructured":""},{"key":"B20","unstructured":"Tumor Immune Estimation Resource\n          \n          2023"},{"key":"B21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/1541-7786.MCR-07-0344","article-title":"Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases","volume":"6","author":"Xu","year":"2008","journal-title":"Mol Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41591-021-01331-8","article-title":"Evolution of delayed resistance to immunotherapy in a melanoma responder","volume":"27","author":"Liu","year":"2021","journal-title":"Nat Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science."},{"key":"B27","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e21594","article-title":"High expression of ferroptosis-sensitizer ACSL4 as an indicator of good response to immune checkpoint inhibitors and preferable survival with increased TIICs in skin cutaneous melanoma","author":"Wu","year":"2021","journal-title":"JCO"},{"key":"B29","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamadermatol.2019.0069","article-title":"Risk factors for lymphatic and hematogenous dissemination in patients with stages I to II cutaneous melanoma","volume":"155","author":"Calomarde-Rees","year":"2019","journal-title":"JAMA Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1553961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:10:11Z","timestamp":1773688211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1553961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":29,"alternative-id":["10.3389\/fmed.2025.1553961"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1553961","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1553961"}}